These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6346344)

  • 1. beta-Pyridylcarbinol (Ronicol) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans.
    Dembińska-Kieć A; Korbut R; Bierón K; Kostka-Trabka E; Gryglewski RJ
    Pharmacol Res Commun; 1983 Apr; 15(4):377-85. PubMed ID: 6346344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Release of disaggregatory prostanoids into circulation by nicotinic alcohol, nicotinic acid and nicotinamide.
    Swies J; Dabrowski L
    Pol J Pharmacol Pharm; 1984; 36(6):653-7. PubMed ID: 6242066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans.
    Grodzińska L; Basista M; Kedzior A; Korbut R; Kostka-Trabka E; Gryglewski R
    Thromb Haemost; 1983 Dec; 50(4):797-9. PubMed ID: 6364447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans.
    Dembińska-Kieć A; Kostka-Trabka E; Zumda A; Byrska-Danek A; Bierón K; Grodzińska L; Kedzior A; Zelazny T
    Pharmacol Res Commun; 1982 Jun; 14(6):485-98. PubMed ID: 6750655
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of beta-pyridylcarbinol (Ronicol) on the myocardial contractility in normal persons.
    Aigner A; Bolzano K; Lisch HJ; Sailer S
    Atherosclerosis; 1974; 20(1):23-5. PubMed ID: 4617580
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of nicotinic acid, nicotinamide, and pyridylcarbinol in pharmacological dosages on lipid metabolism in humans.
    Zöllner N
    Int J Vitam Nutr Res Suppl; 1989; 30():114-9. PubMed ID: 2529321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the lipolysis inhibiting agent beta-pyridylcarbinol (Ronicol) in acute myocardial ischaemia.
    Fazekas T; Szekeres L
    Acta Physiol Hung; 1989; 74(2):169-74. PubMed ID: 2603732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased platelet activity after termination of prostacyclin infusion into man.
    Dembinska-Kiec A; Zmuda A; Grodzinska L; Bieron K; Basista M; Kedzior A; Kostka-Trabka E; Telesz E; Zelazny T
    Prostaglandins; 1981 May; 21(5):827-32. PubMed ID: 6803307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics of a retard preparation of beta-pyridylcarbinol using a new automated assay method].
    Schräpler P; Schulz E; Scholer A
    Med Welt; 1977 Nov; 28(46):1900-3. PubMed ID: 593135
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.
    Szczeklik A; Nizankowski R; Skawinski S; Szczeklik J; Gluszko P; Gryglewski RJ
    Lancet; 1979 May; 1(8126):1111-4. PubMed ID: 86835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of beta-pyridyl-carbinol on platelet aggregation.
    Manzanares J; Cantón R; Zaragoza F
    Thromb Res; 1988 Mar; 49(6):501-8. PubMed ID: 3388307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of prostacyclin (PGI2) by erythrocytes.
    Jakubowski JA; Thompson CB; Deykin D
    Br J Haematol; 1983 Aug; 54(4):658-60. PubMed ID: 6347244
    [No Abstract]   [Full Text] [Related]  

  • 13. Antihyperlipidemic properties of beta-pyridylcarbinol. A review of preclinical studies.
    Cohen M
    Life Sci; 1985 Nov; 37(21):1949-61. PubMed ID: 3906330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans.
    Dembinska-Kiec A; Kostka-Trabka E; Gryglewski RJ
    Thromb Haemost; 1982 Apr; 47(2):190. PubMed ID: 7048622
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythrocyte deformability improving action of beta-pyridylcarbinol tartrate.
    Okada T; Okamoto A; Nakamura K
    Experientia; 1981; 37(8):890-2. PubMed ID: 7286147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of prostacycline, thromboxane A2 and prostaglandins in platelet aggregation (author's transl)].
    Herman AG
    Rev Med Brux; 1981 Mar; 2(3):251-7. PubMed ID: 7015444
    [No Abstract]   [Full Text] [Related]  

  • 17. [Circulatory effect of beta-pyridylcarbinol (Ronicol Roche)].
    GATZEK H; MECHELKE K
    Schweiz Med Wochenschr; 1949 Jun; 79(23):526-8. PubMed ID: 18134097
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical experience on vasodilation by beta-pyridylcarbinol (Ronicol Roche)].
    THURNHEER A; HELLER H
    Schweiz Med Wochenschr; 1949 Jun; 79(23):522-6. PubMed ID: 18134096
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of beta-pyridylcarbinol (Ronicol Roche) in animal experiments].
    FROMHERZ K
    Schweiz Med Wochenschr; 1949 Jun; 79(23):521. PubMed ID: 18134095
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin II stimulation of renal prostaglandin synthesis elevates circulating prostacyclin in the dog.
    Shebuski RJ; Aiken JW
    J Cardiovasc Pharmacol; 1980; 2(5):667-77. PubMed ID: 6157958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.